Telavant

What Telavant does

Telavant was a clinical-stage biopharmaceutical company founded in 2022 and based in Nyack, New York, that was established to develop a TL1A (TNF-like ligand 1A) inhibitor for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis and Crohn's disease. The company's core scientific premise was that TL1A represents a novel cytokine target implicated in gut inflammatory pathophysiology, mechanistically distinct from approved anti-TNF, IL-12/23, and integrin inhibitors, addressing a clear unmet need in moderate-to-severe IBD patients.

Telavant operated with a headcount of 11-50 employees and had no commercial products, no disclosed pricing, no marketing or distribution channels, and no recorded revenue — consistent with a development-stage biotech whose entire value was concentrated in a single late-stage clinical asset. The company had no direct customers in a commercial sense; its downstream end users were patients suffering from ulcerative colitis and Crohn's disease, but no commercial transactions had occurred prior to acquisition.

In 2023, Telavant was acquired by Roche for $7.1 billion, primarily to obtain the TL1A inhibitor asset as part of Roche's strategic expansion into immunology beyond its traditional oncology stronghold. Telavant had been organized as a Roivant Sciences subsidiary, and Roivant recorded a $110.4 million gain from the sale of Telavant's net assets in its FY2025 reporting, reflecting the closing economics of the deal. Following the acquisition, Telavant ceased to operate as an independent entity, and the TL1A program became part of Roche's pipeline rejuvenation strategy targeting 19 new molecular entities by 2030.

Name

Telavant

Website

https://telavanttx.com

Company type

Private

Founded year

2022

Operating status

Acquired

Headcount range

11–50 employees

Short description

Telavant was a clinical-stage biopharmaceutical subsidiary of Roivant Sciences developing a TL1A inhibitor for inflammatory bowel disease (ulcerative colitis and Crohn's disease), and was acquired by Roche in 2023 for $7.1 billion.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Inflammatory bowel disease therapeutics
• Biopharmaceutical drug development
• TL1A inhibitor therapy
• Immunology pipeline assets
• Clinical-stage biotechnology

Headquarters

HQ city

Nyack

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Telavant develops novel medicines for inflammatory and fibrotic disorders, with its lead asset being a TL1A inhibitor in clinical development for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company operated as a single-asset, R&D-stage biopharmaceutical subsidiary of Roivant Sciences prior to being acquired by Roche for $7.1 billion.

Differentiator

Problem solved

Functional benefit

Products and services

• TL1A Inhibitor for Inflammatory Bowel Disease A targeted biologic therapy in clinical development for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. TL1A (TNF-like ligand 1A) is a cytokine involved in inflammatory responses in the gut. The therapy is intended for patients with moderate-to-severe IBD requiring biologic intervention and represents a novel mechanism of action distinct from anti-TNF, IL-12/23, and integrin inhibitors.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• RochecoreStrategic or Co-development Partner · 1 January 2023Roche acquired Telavant for $7.1 billion in 2023 to obtain the TL1A inhibitor for inflammatory bowel disease. This represented Roche's strategy to expand into immunology beyond its traditional oncology stronghold. The acquisition was part of Roche's pipeline rejuvenation strategy with 19 new molecular entities targeted by 2030.

Scale indicators2 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• Prometheus Biosciences: Direct competitor in the TL1A inhibitor space for IBD. Prometheus was acquired by Merck for ~$10.8B in 2023 for its lead TL1A asset (PRA023), making it the closest mechanistic and indication peer to Telavant's program.

Broad incumbents

• AbbVie: Established immunology leader with Humira, Skyrizi, and Rinvoq dominating the IBD market. AbbVie represents the incumbent competitive benchmark that any new TL1A entrant must displace or combine with.
• Johnson & Johnson (Innovative Medicine): Markets Stelara and Tremfya for IBD and other inflammatory diseases. J&J is a broad incumbent whose established IL-12/23 and IL-23 franchises compete directly with Telavant's TL1A program for IBD share.
• Takeda Pharmaceutical: Markets Entyvio (vedolizumab), an integrin inhibitor widely used in ulcerative colitis and Crohn's disease. Takeda is a major incumbent competitor in the IBD biologic space.
• Eli Lilly: Developed mirikizumab (Omvoh) for ulcerative colitis and Crohn's disease, competing in the IL-23 IBD class. Lilly is a broad incumbent whose immunology pipeline directly overlaps Telavant's target indications.
• Bristol Myers Squibb: Markets Zeposia (ozanimod) for ulcerative colitis and has an active immunology pipeline including TYK2 and other inflammatory programs. BMS is a relevant incumbent competitor in IBD and adjacent inflammatory indications.
• Sanofi: Pursues its own TL1A program (and broader immunology franchise including Dupixent). Sanofi is a relevant peer given overlapping TL1A mechanism interest and comparable IBD/inflammation strategic positioning.
• Merck & Co. Acquired Prometheus Biosciences for ~$10.8B to gain its TL1A inhibitor, making Merck the most direct big-pharma competitor to Roche/Telavant in the TL1A mechanism for IBD.
• Pfizer: Acquired Arena Pharmaceuticals and markets etrasimod for ulcerative colitis. Pfizer is a relevant incumbent competitor in IBD with overlapping oral and biologic inflammation programs.

Others

• Roivant Sciences: Former parent of Telavant and operator of the 'Vant' platform that built and divested the asset. Roivant is thematically comparable as the developer/seller and continues to incubate similar inflammation and immunology biotechs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Telavant